T. Rowe Price Associates’s Nautilus Biotechnolgy NAUT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-16,078
Closed -$14K 3118
2025
Q1
$14K Hold
16,078
﹤0.01% 3019
2024
Q4
$28K Hold
16,078
﹤0.01% 2981
2024
Q3
$46K Hold
16,078
﹤0.01% 2938
2024
Q2
$38K Hold
16,078
﹤0.01% 2883
2024
Q1
$48K Buy
16,078
+4,239
+36% +$12K ﹤0.01% 2877
2023
Q4
$36K Buy
11,839
+1,389
+13% +$3.97K ﹤0.01% 2844
2023
Q3
$34K Buy
10,450
+438
+4% +$1.43K ﹤0.01% 2822
2023
Q2
$39K Buy
+10,012
New +$28.8K ﹤0.01% 2827

Other funds holding NAUT

T. Rowe Price Associates's NAUT Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Nautilus Biotechnolgy (NAUT) in Q2 2025, closing a stake of 16,078 shares — an estimated $14K sold.

T. Rowe Price Associates first reported a position in NAUT in Q2 2023 and held it in 8 quarters. The position peaked at $48K in Q1 2024. 71 funds tracked by Wall St. Rank hold NAUT as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Nautilus Biotechnolgy position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 16,078 Nautilus Biotechnolgy shares in Q2 2025, an estimated $14K.
  • T. Rowe Price Associates first reported a position in Nautilus Biotechnolgy in Q2 2023 and held it in 8 quarters.
  • T. Rowe Price Associates's Nautilus Biotechnolgy position peaked at $48K in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.